BioNexus Gene Lab Corp (BGLC) has a current Price-to-Book (P/B) ratio of 1.04. Compared to its 3-year average P/B ratio of 2.37, the current P/B ratio is approximately -56.10% higher. Relative to its 5-year average P/B ratio of 11.25, the current P/B ratio is about -90.77% higher. BioNexus Gene Lab Corp (BGLC) has a Forward Free Cash Flow (FCF) yield of approximately -29.65%. Compared to its 3-year average FCF yield of -24.60%, the current FCF yield is approximately 20.52% lower. Relative to its 5-year average FCF yield of -18.09%, the current FCF yield is about 63.85% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BGLC competitors is 0.02, providing a benchmark for relative valuation. BioNexus Gene Lab Corp Corp (BGLC.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of -3.29%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BGLC increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BGLC in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BGLC currently overvalued or undervalued?

What is BioNexus Gene Lab Corp (BGLC) fair value?

BGLC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of BioNexus Gene Lab Corp (BGLC) is between to according to relative valuation method.

How does BGLC's valuation metrics compare to the industry average?

The average P/S ratio for BGLC's competitors is 0.02, providing a benchmark for relative valuation. BioNexus Gene Lab Corp Corp (BGLC) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -3.29%, this premium appears unsustainable.

What is the current P/B ratio for BioNexus Gene Lab Corp (BGLC) as of Mar 02 2026?

As of Mar 02 2026, BioNexus Gene Lab Corp (BGLC) has a P/B ratio of 1.04. This indicates that the market values BGLC at 1.04 times its book value.

What is the current FCF Yield for BioNexus Gene Lab Corp (BGLC) as of Mar 02 2026?

As of Mar 02 2026, BioNexus Gene Lab Corp (BGLC) has a FCF Yield of -29.65%. This means that for every dollar of BioNexus Gene Lab Corp's market capitalization, the company generates -29.65 cents in free cash flow.

What is the current Forward P/E ratio for BioNexus Gene Lab Corp (BGLC) as of Mar 02 2026?

As of Mar 02 2026, BioNexus Gene Lab Corp (BGLC) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of BioNexus Gene Lab Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for BioNexus Gene Lab Corp (BGLC) as of Mar 02 2026?

As of Mar 02 2026, BioNexus Gene Lab Corp (BGLC) has a Forward P/S ratio of 0.00. This means the market is valuing BGLC at $0.00 for every dollar of expected revenue over the next 12 months.

BGLC Valuation